Nationwide Surveillance of Novel Oxazolidinone Resistance Gene optrA in Enterococcus Isolates in China from 2004 to 2014-Reference-Cited by-同舟云学术

Nationwide Surveillance of Novel Oxazolidinone Resistance Gene optrA in Enterococcus Isolates in China from 2004 to 2014

Published:2016-12 Issue:12 Volume:60 Page:7490-7493
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cui Lanqing¹,Wang Yang²,Lv Yuan¹,Wang Shan¹,Song Yunjia¹,Li Yun¹,Liu Jian¹,Xue Feng¹,Yang Weiwei¹,Zhang Jia¹

Affiliation:

1. Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China

2. Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing, China

Abstract

ABSTRACT A total of 2,201 nonduplicate enterococcal isolates collected from 29 hospitals in 23 cities in China between 2004 and 2014 were screened for the oxazolidinone resistance gene optrA ; 45 isolates (2.0%) were optrA positive with 11 OptrA variants identified. The positive rate of optrA increased from 0.4% to 3.9% during the 10-year surveillance period. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence type (MLST) analysis revealed that 37 optrA -positive Enterococcus faecalis isolates clustered into 25 PFGE patterns and 21 sequence types, while 6 Enterococcus faecium isolates represented 6 PFGE patterns and 6 sequence types. The present study underscores the importance of routine and persistent monitoring of oxazolidinone resistance and optrA gene.

Funder

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01256-16

Reference15 articles.

1. Linezolid, the first oxazolidinone antibacterial agent

2. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014)

3. Surveillance for linezolid resistance via the Zyvox®Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates